Precision medicine, the tailoring of healthcare based on an individual's genetics, lifestyle and environment, has been used with success in monogenic diabetes but several barriers have prevented its large-scale application throughout diabetes. In this issue, a series of reviews outline previous achievements, current limitations and future promises of precision diabetes: Hattersley and Patel (DOI 10.1007/s00125-017-4226-2) discuss its application in monogenic diabetes, including challenges faced when implementing this approach into clinical care. In terms of diabetes prevention, Giles Yeo (DOI 10.1007/ s00125-016-4187-x) describes the use of precision medicine for the management of obesity, whilst Franks and Poveda (DOI 10.1007/s00125-017-4207-5) discuss its use to predict response to deleterious lifestyle factors and, conversely, to lifestyle interventions. Mark McCarthy (DOI 10.1007/s00125-017-4210-x) proposes a new model (the 'palette model') for precision diabetes that accounts for the multifactorial nature of diabetes and the impact of therapeutic agents on diabetes risk and progression. Finally, Jose Florez (DOI 10.1007/s00125-017-4227-1) explains how pharmacogenetics may be used to elucidate new drug targets, uncover pathophysiology, unravel disease heterogeneity and identify genes that contribute to diabetes risk. In summary, this precision medicine series suggests a new horizon in diabetes care but does not dismiss the enormous amount of work that remains necessary for large-scale application of this promising approach. This review set is accompanied by an editorial by Sally Marshall (DOI 10.1007/s00125-017-4244-0).
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Melatonin signalling and type 2 diabetes risk: is it a case of too little or too much?
Commentaries by: Amélie Bonnefond, Philippe Froguel; Hindrik Mulder Sweet dreams or nightmares? Human genetics provides a powerful tool for identifying causal pathways and relationships of disease risk. In the field, it is well recognised that genetic variation in and near MTNR1B influences type 2 diabetes risk but finding consensus on the molecular mechanisms that bring about this effect is still an area of hot debate and current research activity. In this issue, we feature a review by Forrestel et al (DOI 10.1007/ s00125-016-4175-1; see below), summarising our current knowledge of melatonin in diabetes. In addition, because this is currently such a controversial field, we have commissioned two articles from laboratories that are Competition for publication in Diabetologia continues to grow, and less than 20% of papers are accepted. Of all the high-quality papers that appear in this month's issue I want to draw your attention to five articles that I think are particularly interesting. The articles are summarised here. Our publisher, Springer, has kindly made the full text of each of these papers freely available. I hope you enjoy reading them! Sally M. Marshall, Editor leading research to understand the role of genetic variation in the melatonin receptor in diabetes risk: Bonnefond and Froguel (DOI 10.1007/s00125-017-4255-x) make a case for the detrimental impact of too little melatonin signalling on type 2 diabetes risk, whilst Hindrik Mulder (DOI 10.1007/ s00125-017-4249-8) outlines evidence for the negative effect of both elevated and reduced melatonin signalling on diabetes risk. These authors present their opinions on the interpretation of the current landscape and thoughts on how the field might resolve them.
Chronomedicine and type 2 diabetes: shining some light on melatonin
Circadian timing systems are almost universally present in living organisms, from unicellular to mammalian species. In mammals (including humans), the timing system makes a sizeable contribution to insulin secretion and glucose metabolism processes. Pineal melatonin, known primarily for its role as a 'sleep hormone' , is a principal mediator of human circadian rhythms. Disruption of this system is associated with obesity, dysglycaemia and other metabolic disturbances. In this issue, Forrestel et al (DOI 10.1007/ s00125-016-4175-1) review the regulation of circadian rhythmicity, paying specific attention to the metabolic consequences of its disruption. Focus is placed on the impact of melatonin on metabolic processes, especially insulin secretion, and the consequences of melatonin receptor polymorphisms on glucose homeostasis and diabetes risk. Interestingly, melatonin levels are reduced in individuals with diabetes. In line with this, the authors provide a clinical perspective on the use of melatonin as a potential chronotherapy for the management of diabetes, discussing the pros and cons of melatonin therapy for glycaemic control. They conclude by highlighting the need for more dedicated study of chronopharmacological agents, such as melatonin, for the treatment of metabolic diseases.
Prolonged sitting may increase diabetes risk in physically inactive individuals: an 11 year follow-up of the HUNT Study, Norway Bjørn O. Åsvold, Kristian Midthjell, Steinar Krokstad, Vegar Rangul, Adrian Bauman Emerging evidence indicates that prolonged sitting may have adverse effects on blood glucose levels and insulin sensitivity, but few studies have examined the association between total daily sitting time and the risk of diabetes. In this issue, Åsvold et al (DOI 10.1007/s00125-016-4193-z) report the association between total sitting time and the risk of diabetes during an 11 year follow-up of the population-based Nord-Trøndelag Health Study (the HUNT Study). Total sitting time had little association with diabetes risk in the population as a whole. However, among physically inactive individuals, sitting Q8 h/day was associated with a 30% increased risk of diabetes compared with sitting e4 h/day. The results suggest that prolonged sitting may contribute to increased risk of diabetes among physically inactive people. Fasting plasma levels of branched-chain amino acids (BCAA) are associated with peripheral insulin resistance. However, it is unclear whether this association is due to a causal link between BCAA levels and insulin resistance. In this issue, Mahendran et al (DOI 10.1007/s00125-017-4222-6) report that a genetically-determined increase in circulating BCAA levels does not lead to more severe insulin resistance. In contrast, a genetically-determined increase in the severity of insulin resistance resulted in elevated circulating BCAA levels. The authors conclude that the association between circulating BCAA levels and insulin resistance likely reflects a causal effect of insulin resistance on BCAA levels; this may be explained by the impact of insulin (a chief regulator of amino acid metabolism) on the rate of appearance and clearance of BCAA together with decreased activity of catabolic enzymes involved in BCAA metabolism. In summary, increased BCAA levels in individuals with insulin resistance appears to be a marker of impaired insulin action rather than a causative factor.
Glucose and fatty acids synergistically and reversibly promote beta cell proliferation in rats Valentine S. Moullé, Kevin Vivot, Caroline Tremblay, Bader Zarrouki, Julien Ghislain, Vincent Poitout
The mechanisms by which glucose homeostasis is maintained in the face of insulin resistance involve, at least in part, an increase in pancreatic beta cell mass via proliferation. Since failure of this compensatory response leads to type 2 diabetes, understanding its underlying mechanism is clinically relevant. In this issue, Moullé et al (DOI 10.1007/s00125-016-4197-8) report the effects of glucose and NEFA, alone or in combination, on beta cell proliferation. Using complementary in vivo studies in rats and ex vivo studies in isolated rat and human islets, the authors showed that glucose and NEFA synergistically and reversibly stimulated beta cell proliferation via several mechanisms, including via direct effect of these nutrients. Furthermore, nutrient-induced endogenous circulating factors released in response to insulin resistance potentiated beta cell proliferation. Importantly, nutrient-induced beta cell proliferation was independent from secreted insulin. These findings underscore the complexity of the beta cell response to nutrient excess in vivo.
Combined NOX1/4 inhibition with GKT137831 in mice provides dose-dependent reno-and atheroprotection even in established micro-and macrovascular disease
Stephen P. Gray, Jay C. Jha, Kit Kennedy, Erik van Bommel, Phyllis Chew, Cedric Szyndralewiez, Rhian M. Touyz, Harald H. H. W. Schmidt, Mark E. Cooper, Karin A. M. Jandeleit-Dahm
Oxidative stress derived from NADPH oxidase (NOX)1 and NOX4 has been reported to contribute to the development of diabetic complications, in particular diabetesaccelerated atherosclerosis and kidney disease. However, it has not yet been tested whether NOX-targeted drug intervention in established disease can prevent diabetes progression. In this issue, Gray et al (DOI 10.1007/s00125-017-4215-5) report that administration of a novel NOX inhibitor that prevents NOX1-and NOX4-derived oxidative stress halts the progression of kidney disease and the development of atherosclerosis. Tissue-specific and dose-dependent effects were evident in the response to NOX inhibition, particularly with regards to its impact on atherosclerosis progression. These studies highlight the importance of defining the optimal relative balance between NOX1 and NOX4 inhibition in the micro-and macrovasculature for the management of diabetes.
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